IKB
3
25M
3
0.03
2
- Areas of investment
Summary
IKB appeared to be the Corporate Investor, which was created in 1924. The main department of described Corporate Investor is located in the Du00fcsseldorf. The company was established in Europe in Germany.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the IKB, startups are often financed by Techno Venture Management, AlpInvest Partners, Qiagen. The meaningful sponsors for the fund in investment in the same round are Techno Venture Management, KBL Healthcare Ventures, AlpInvest Partners. In the next rounds fund is usually obtained by Techno Venture Management, AlpInvest Partners, Vontobel.
Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - Germany. Among the most successful fund investment fields, there are Manufacturing, Biotechnology. Among the most popular portfolio startups of the fund, we may highlight Cardion, EpiCept Corporation, EpiCept Corporation.
The higher amount of exits for fund were in 2012. The fund is constantly included in less than 2 deals per year. This IKB works on 38 percentage points more the average amount of lead investments comparing to the other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars. The important activity for fund was in 2000.
Investments analytics
Analytics
- Total investments
- 3
- Lead investments
- 0
- Exits
- 2
- Rounds per year
- 0.03
- Investments by industry
- Biotechnology (2)
- Information Technology (1)
- Genetics (1)
- Medical (1)
- Biopharma (1)
- Investments by region
-
- Germany (2)
- United States (1)
- Peak activity year
- 2000
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 26
- Group Appearance index
- 1.00
- Avg. company exit year
- 14
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Ingenium Pharmaceuticals AG | 01 Oct 2000 | Biotechnology | Early Stage Venture | 59M | Germany, Bavaria, Germany |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.